Fate Therapeutics, Inc. (FATE) Market Cap & Valuation Ratios
Fate Therapeutics, Inc. (FATE) has a market cap of $252.8M and a price-to-sales ratio of 39.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FATEFate Therapeutics, Inc.Follow FATE — free
—
Price chart with a free account
- Market cap
- 252.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| FATE | 0.3 | — | 15.3 | — | — | -23% | — | -78% |
| FULC | 0.3 | — | — | — | — | — | — | -44% |
| ARCT | 0.3 | — | 3.0 | — | — | -76% | -348% | — |
| RCKT | 0.3 | — | — | — | — | — | — | -82% |
| OCGN | 0.3 | — | 51.3 | — | — | -4% | — | — |
| LRMR | 0.2 | — | — | — | — | — | — | -267% |
| VNDA | 0.2 | — | 0.9 | — | — | +6% | -86% | -65% |
| DRUG | 0.2 | — | — | — | — | +4943% | — | — |
| PALI | 0.2 | — | — | — | — | — | — | — |
| LXEO | 0.2 | — | — | — | — | — | — | -78% |
| KROS | 0.2 | — | — | — | — | -94% | — | -956% |
| Median of these 10 | — | 3.0 | — | — | -4% | -217% | -80% |
; EV/Sales 15.3 vs. 3.0.
Growth vs. price
each dot a company · hover or tap for valuesFate Therapeutics, Inc. — questions
- What is Fate Therapeutics, Inc.'s market cap?
- $252.8M.
- What is Fate Therapeutics, Inc.'s price-to-sales ratio?
- 39.0.
Every figure on this page comes from Fate Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.